Recentadvances in understanding the progression or development of chondrosarcoma havesuggested several molecular targets for future development of new adjuvanttherapy [16], such as chondrocyte differentiation factors (PTHrP, CTGF) [17, 18], antiapoptotic gene (Bcl-2) [19, 20], tumor suppressor gene (p16, p53) [21, 22], and others (PDGF-α, VEGF, MDR-1)[23–25]. Here, CDKN2A is linked to chondrosarcoma.